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We examined the effect of salivary cortisol on cognitive performance and decline in 3229 adults (79%
men), mean age 61 years. Six saliva samples over the day along with a cognition test battery were
administered twice in 5 years. In fully-adjusted cross-sectional analyses from 2002 to 2004, higher
waking cortisol was associated with higher reasoning score (b ¼ 0.08, 95% conﬁdence interval: 0.01, 0.15)
but this ﬁnding was not replicated using data from 2007 to 2009. Over the mean 5 years follow-up there
was decline in all cognitive tests but this decline did not vary as a function of cortisol levels; the
exception was among APOE e4 carriers where a ﬂatter diurnal slope and higher bedtime cortisol were
associated with faster decline in verbal ﬂuency. Changes in cortisol measures between 2002/2004 and
2007/2009 or chronically elevated levels were not associated with cognitive performance in 2007/2009.
These results, based on a large sample of community-dwelling adults suggest that variability in
hypothalamic-pituitary-adrenal function is not a strong contributor to cognitive aging.
 2014 The Authors. Published by Elsevier Inc. All rights reserved.1. Introduction
Cortisol is a glucocorticoid hormone, regulated via the
hypothalamic-pituitary-adrenal (HPA) axis. Dysregulation of this
axis is hypothesized to impair cognitive function, in particular
memory and learning processes (Sapolsky et al., 1986, 2000). Much
of the evidence for this view comes from animal models where
glucocorticoid receptors have been found in the rodent hippo-
campus (Jacobson and Sapolsky, 1991; McEwen et al., 1986), and
elevated glucocorticoid levels shown to be associated with spatial
memory impairments and neuronal loss in the hippocampus (Issa
et al., 1990; Montaron et al., 2006). Small experimental studies in
humans show short term elevations in cortisol improve consoli-
dation of memories (Abercrombie et al., 2003; Buchanan and
Lovallo, 2001; Kuhlmann and Wolf, 2006). However, sustained el-
evations in cortisol may be toxic to brain cells, as in Cushing diseasee CC BY license (http://
for Research in Epidemiology
/16, 16 Avenue Paul Vaillant
77 74 74 10; fax: þ33 (0)1 77
(A. Singh-Manoux).
Published by Elsevier Inc. All righ(Starkman et al., 1992) and contribute to risk of dementia. Dementia
patients show higher cortisol levels (Elgh et al., 2006; Hartmann
et al., 1997) but no disturbance in the diurnal rhythm (Hartmann
et al., 1997). Neuroimaging data show plasma cortisol to be corre-
lated with beta amyloid, a hallmark of Alzheimer’s disease (Toledo
et al., 2012). However, given the long preclinical phase of dementia
(Braak and Del, 2011; Jack et al., 2010) it is unclear whether HPA
dysregulation is a cause, correlate, or consequence of dementia.
Evidence of an association between elevated cortisol levels and
accelerated cognitive decline would support an etiological role for
cortisol.
There is some evidence, mostly from studies of limited size on
elderly persons (Lupien et al., 1994, 1998) that memory is the
domain speciﬁcally affected by higher cortisol levels. While gluco-
corticoid receptors are localized to the rodent hippocampus
(Jacobson and Sapolsky, 1991; McEwen et al., 1986), they are widely
present in primate brains (Sanchez et al., 2000), making it impor-
tant to consider the association of cortisol with a wide range of
cognitive domains. The measurement of cortisol is not straightfor-
ward, salivary cortisol over the day is seen to better measure HPA
axis function compared with plasma or urinary cortisol
(Kirschbaum and Hellhammer, 1989, 1994; Vining et al., 1983). In
this article, we examined the association of salivary cortisol,ts reserved.
A. Singh-Manoux et al. / Neurobiology of Aging 35 (2014) 2239e22452240assessed with 6 samples over the day, and cognitive decline over a
5-year period in a large cohort of middle-aged community-dwell-
ing adults. Since APOE e4 is a risk factor for both cognitive decline
before the age of 60 years (Caselli et al., 2009) and dementia (Corder
et al., 1993) and is hypothesized to modify cortisol’s association
with cognitive function (Lee et al., 2008), we also conducted ana-
lyses stratiﬁed by APOE ε4 status. We used tests of memory,
reasoning, and verbal ﬂuency in the analysis.
2. Methods
2.1. Participants
The Whitehall II study is an ongoing study of men and women,
originally employed by the British civil service. The target popula-
tion was all London-based ofﬁce staff, aged 35e55 years at study
inception. A total of 10,308 persons (6895 men and 3413 women),
response rate 73%, were recruited to the study in 1985e1988
(Marmot and Brunner, 2005). Since the baseline medical exami-
nation, follow-up examinations have taken place approximately
every 5 years: 1991/1993 (n ¼ 8815); 1997/1999 (n ¼ 7870); 2002/
2004 (n ¼ 6967), and 2007/2009 (n ¼ 6761). Ethical approval for
the Whitehall II study was obtained from the University College
LondonMedical School committee on the ethics of human research;
all participants provided written informed consent.
2.2. Assessment of cortisol, 2002/2004 and 2007/2009
Cortisol data collectionwas initiated part way through the 2002/
2004 wave and repeated in 2007/2009. Instructions were given in a
face-to-face interview where participants were requested to pro-
vide 6 saliva samples using salivettes over the course of a normal
weekday at waking,þ30 minutes,þ2.5 hours,þ8 hours,þ12 hours,
and bedtime. The intention was to study diurnal rhythm, charac-
terized by high levels upon waking, a further increaseepeaking at
about 30e40 minutes (the cortisol awakening response, CAR) and
subsequent decline over the remainder of the day (Kirschbaum and
Hellhammer, 1989). Participants were instructed not to brush their
teeth or eat or drink for 15 minutes before sample collection. A
booklet was used for participants to record information on the day
of sampling including date of collection, wake time, and time each
sample was taken. The salivettes and booklet were returned in a
prepaid envelope by post. Salivettes were centrifuged at 3000 rpm
for 5 minutes, resulting in a clear supernatant of low viscosity.
Salivary cortisol levels were measured using a commercial immu-
noassay with chemiluminescence detection (CLIA; IBLHamburg,
Hamburg, Germany). The lower concentration limit of this assay
was 0.44 nmol/liter; intra and interassay coefﬁcients of variance
were below 8%.
2.3. Cognitive function, 2002/2004 and 2007/2009
The cognitive test battery was chosen to provide a compre-
hensive assessment of cognitive function while being appropriate,
with respect to ceiling effects, for this population composed of in-
dividuals younger than inmost studies on cognitive aging. The tests
had high testeretest reliability, range 0.60e0.89, assessed on 556
participants within 3months of having taken the test in 2002/2004.
Short-term verbal memory was assessed with a free recall test.
Participants were presented a list of 20 one or 2 syllable words at 2
seconds intervals and were then asked to recall in writing, within 2
minutes, as many words as possible, in any order.
The Alice Heim 4-I is composed of a series of 65 verbal and
mathematical reasoning items of increasing difﬁculty (Heim, 1970).
It tests inductive reasoning, measuring the ability to identifypatterns and infer principles and rules. Participants had 10 minutes
to do this section.
Verbal ﬂuency (Borkowski et al., 1967), phonemic, and semantic
tests were combined for the purposes of the analysis. Participants
were asked to recall in writing as many words beginning with “S”
(phonemic ﬂuency) and as many animal names (semantic ﬂuency)
as they could. One minute was allowed for each test; the observed
range on these tests was 0e35.
2.4. Covariates
Demographic measures included age, sex, ethnicity (white, non-
white), and education, deﬁned as the highest qualiﬁcation on
leaving full-time education and categorized as lower secondary
school or less, higher secondary school (usually achieved at the age
of 18 years) and university or higher degree. Other covariates in the
analyses were seasonality (using 21 March, June, September, and
December as cutoffs); depressive symptoms using the 20-item
Center for Epidemiologic Studies Depression Scale; (Radloff, 1997)
stress on the day of cortisol sampling using questions on whether
the participant had experienced a stressful event and, if yes,
response to how stressful this was on a 5 point Likert-scale; car-
diovascular risk using the Framingham general cardiovascular dis-
ease risk score which includes age, sex, systolic blood pressure,
treatment for hypertension, high density lipoprotein cholesterol,
total cholesterol, smoking, and diabetes (D’Agostino et al., 2008);
coronary heart disease and stroke identiﬁed using linkage to na-
tional hospital records, diabetes mellitus determined by fasting
glucose 7.0 mmol/L, a 2-hour postload glucose 11.1 mmol/L,
reported doctor-diagnosed diabetes, or use of diabetes medication;
and medication to treat cardiovascular risk factors and depression.
For the sensitivity analysis, we assessed APOE genotype. Two
TaqMan assays (Rs429358 and Rs7412, Assay-On-Demand, Applied
Biosystems) were used and run on a 7900HT analyzer (Applied
Biosystems), and genotypes indicated by the Sequence Detection
Software version 2.0 (Applied Biosystems). Participants were cate-
gorized as APOE ε4 carriers for those with at least 1 ε4 allele.
2.5. Statistical analysis
All analyses were conducted using STATA 12. Participant char-
acteristics were described using percentages, or mean (standard
deviation, SD) when appropriate, as a function of sex. Five param-
eters were used to operationalize diurnal cortisol patterns in the
analysis: (1) waking cortisol, the ﬁrst measure of the day; (2) CAR,
cortisol awakening response calculated by subtracting cortisol
measured at time 1 (waking) from cortisol measured at time 2
(þ30 minutes); (3) diurnal slope to reﬂect the decline in cortisol
levels over the day, calculated by regressing logarithmically trans-
formed cortisol values (excluding cortisol at time 2 so that slope
across the day is not unduly biased by CAR) against sample time
using a hierarchical linear model (random slope and intercept)
where measurement occasion was a level 1 identiﬁer and person a
level 2 identiﬁer, lower (more negative) slopes indicate a more
rapid decline in cortisol levels, whereas slope values closer to zero
reﬂect ﬂatter diurnal rhythms; (4) bedtime cortisol, the last mea-
sure of the day; and (5) mean cortisol over the day, using the area
under the curve (Pruessner et al., 2003), this measure was derived
using the trapezoid formula and then divided by the time between
the ﬁrst and the last measure of the day for each person to yield
mean hourly cortisol.
All 5 measures were categorized into tertiles; we also ran
analyses using continuous scores, modeled as an increment of 1
standard deviation after log transforming the values which showed
a skewed distribution (waking and bedtime cortisol). Linear
Table 1
Sample characteristics in 2002/2004 according to sex
Men Women p
N 2541 688
Age, M (SD) 60.8 (5.8) 61.1 (5.9) 0.25
High education, % 33.8 19.8 <0.001
White, % 95.0 88.8 <0.001
Cortisol
Waking cortisol (nmol/L), M (SD)a 14.29 (1.80) 13.25 (1.81) 0.003
CAR (nmol/L), M (SD) 7.09 (11.19) 8.73 (2.73) 0.05
Diurnal slope (nmol/L), M (SD) 0.130 (0.025) 0.133 (0.023) 0.03
Bedtime cortisol (nmol/L), M (SD)a 1.57 (2.52) 1.69 (2.43) 0.06
Mean cortisol (nmol/L), M (SD) 7.41 (2.80) 6.71 (2.45) <0.001
Cognition
Memory (range 0e20), M (SD) 6.9 (2.3) 7.1 (2.6) 0.11
Reasoning (range 0.65), M (SD) 46.2 (9.6) 40.0 (11.8) <0.001
Fluency (range 0.35), M (SD) 16.0 (3.3) 15.6 (3.8) 0.02
Key: CAR, cortisol-awakening response; M, mean; SD, standard deviation.
a Geometric mean.
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nal association of cortisol measures with cognition, using stan-
dardized cognitive test scores (mean ¼ 0; standard deviation ¼ 1).
For the analysis of cognitive decline the standardization was un-
dertaken using the 2002/2004 measure, such that the distribution
of the baseline was also used to standardize the follow-up data;
difference in the standardized scores between the 2 assessments
(2007/2009 scoree2002/2004 score) was the outcome. These an-
alyses were adjusted for age, sex, ethnicity, education, time of
waking, the delay between waking and ﬁrst cortisol assessment,
seasonality, depressive symptoms, stress, Framingham cardiovas-
cular risk score, coronary heart disease, stroke, diabetes, medication
for cardiovascular disease (CVD), and antidepressants. Finally, we
examined whether changes in cortisol measures between 2002/
2004 and 2007/2009 were associated with cognition in 2007/2009.
This also included assessing the association of low and high cortisol
levels at both time-points with cognitive performance at the second
time-point by categorizing participants as being in the ﬁrst tertile of
cortisol distribution at both assessments, being in the third tertile
and others.
In sensitivity analyses we reran the cross-sectional analysis us-
ing data from the 2007/2009 assessment, undertook analysis of
cognitive decline using the growth curve approach (Laird andWare,
1982), conducted the longitudinal analysis separately in men and
women, and ﬁnally in analysis stratiﬁed by APOE e4 status.3. Results
In 2002/2004, a total of 4498 participants provided cortisol data.
After excluding thosewho reported taking steroidmedications (239
corticosteroids and 175 female sex hormones), those with cortisol
values outside 3 SD from the mean (n ¼ 91) or incomplete cortisol
data (n ¼ 354), we were left with 3736 participants. Those non-
complaint on the cortisol protocol (n ¼ 354) excluded from the
analyses, were more likely to be female (26.5% were womenTable 2
Cross-sectional association between cortisol and cognitive function, assessed in 2002/20
Cortisol measures M (SD) nmol/L Cognitive fu
Memory
Beta (95% CI
Waking cortisol (tertile) 8.20 (2.65) REF
14.88 (1.82) 0.02 (0.0
25.24 (6.37) 0.00 (0.0
1 SD increment, log 0.00 (0.0
CAR (tertile) 4.58 (5.91) REF
6.55 (2.51) 0.03 (0.0
19.38 (7.69) 0.05 (0.0
1 SD increment 0.01 (0.0
Diurnal slope (tertile) 0.16 (0.02) REF
0.13 (0.01) 0.04 (0.1
0.10 (0.01) 0.06 (0.1
1 SD increment 0.02 (0.0
Bedtime cortisol (tertile) 0.71 (0.29) REF
1.67 (0.32) 0.06 (0.1
5.04 (4.56) 0.07 (0.1
1 SD increment, log 0.02 (0.0
Mean cortisol (tertile) 4.66 (0.96) REF
6.85 (0.59) 0.00 (0.0
10.26 (2.34) 0.01 (0.0
1 SD increment 0.00 (0.0
Analysis adjusted for age, sex, education, ethnicity, waking time, time between waking
cardiovascular risk score, coronary heart disease, stroke, diabetes, medication for cardio
N ¼ 3229.
Key: AH 4-I, Alice Heim 4-I; CAR, cortisol-awakening response; CI, conﬁdence interval; M
a Cognitive data have been converted to z-scores for the analysis.
b p < 0.05.compared with 21.3% in the analytic sample, p ¼ 0.02) but not age
(p ¼ 0.30) or education (p ¼ 0.16) differences were observed. The
main analysis was undertaken on 3229 of these participants with
cognitive data in 2002/2004 and 2007/2009. Compared with 1269
(4498 in 2002/2004e3229 in the analysis) participants excluded
from the current analyses, the analytic sample consisted of younger
(60.8 vs. 61.6 years, p < 0.001) participants, more men (78.7% vs.
62.9%, p < 0.001), and more educated individuals (30.8% vs. 27.3%
had a university degree, p ¼ 0.001).
Table 1 presents the sample characteristics of men and women;
although there were sex differences in cortisol values we combined
men and women in the analysis as the cortisol-cognition associa-
tions showed no sex differences (all p for interaction >0.05). The
cross-sectional association between cortisol and cognitive function
at the 2002/2004 assessment (Table 2) show higher waking cortisol
to be associated with higher reasoning scores (b ¼ 0.08, 95% con-
ﬁdence interval [CI]: 0.00, 0.15), the same analysis with the 2007/04a
nction
Reasoning (AH 4-I) Verbal ﬂuency
) Beta (95% CI) Beta (95% CI)
REF REF
6, 0.10) 0.03 (0.04, 0.10) 0.00 (0.08, 0.08)
8, 0.08) 0.08 (0.00, 0.15)b 0.01 (0.09, 0.06)
3, 0.03) 0.02 (0.01, 0.05) 0.01 (0.04, 0.02)
REF REF
5, 0.11) 0.02 (0.05, 0.09) 0.06 (0.01, 0.14)
3, 0.13) 0.05 (0.12, 0.03) 0.06 (0.02, 0.13)
2, 0.05) 0.03 (0.05, 0.00) 0.01 (0.03, 0.04)
REF REF
2, 0.04) 0.00 (0.07, 0.07) 0.00 (0.07, 0.08)
5, 0.02) 0.02 (0.06, 0.09) 0.05 (0.13, 0.03)
6, 0.01) 0.00 (0.03, 0.02) 0.02 (0.05, 0.01)
REF REF
4, 0.02) 0.01 (0.06, 0.08) 0.00 (0.07, 0.08)
5, 0.01) 0.01 (0.08, 0.06) 0.04 (0.12, 0.03)
6, 0.01) 0.01 (0.04, 0.02) 0.01 (0.05, 0.02)
REF REF
8, 0.08) 0.01 (0.06, 0.08) 0.03 (0.04, 0.11)
7, 0.10) 0.02 (0.05, 0.09) 0.02 (0.06, 0.10)
3, 0.04) 0.00 (0.03, 0.03) 0.01 (0.04, 0.02)
and ﬁrst measure of cortisol, seasonality, depressive symptoms, stress, Framingham
vascular disease, and antidepressants.
, mean; REF, reference; SD, standard deviation.
Table 3
Cortisol in 2002/2004 as a predictor of cognitive decline between 2002/2004 and 2007/2009a
Cortisol measures M (SD) nmol/L Cognitive function
Memory Reasoning (AH 4-I) Verbal ﬂuency
Beta (95% CI) Beta (95% CI) Beta (95% CI)
Waking cortisol (tertile) 8.20 (2.65) REFb (beta ¼ 0.28)c REFb (beta ¼ 0.07)c REFb (beta ¼ 0.16)c
14.88 (1.82) 0.01 (0.07, 0.09) 0.04 (0.00, 0.09)d 0.01 (0.05, 0.07)
25.24 (6.37) 0.01 (0.10, 0.07) 0.00 (0.04, 0.04) 0.01 (0.05, 0.06)
1 SD increment, log 0.01 (0.04, 0.03) 0.00 (0.02, 0.02) 0.00 (0.02, 0.03)
CAR (tertile) 4.58 (5.90) REFb (beta ¼ 0.29)c REFb (beta ¼ 0.06)c REFb (beta ¼ 0.13)c
6.55 (2.51) 0.01 (0.07, 0.10) 0.01 (0.03, 0.06) 0.05 (0.11, 0.01)
19.38 (7.69) 0.00 (0.08, 0.08) 0.02 (0.06, 0.02) 0.03 (0.09, 0.03)
1 SD increment 0.00 (0.03, 0.04) 0.01 (0.02, 0.01) 0.01 (0.03, 0.02)
Diurnal slope (tertile) 0.16 (0.02) REFb (beta ¼ 0.30)c REFb (beta ¼ 0.04)c REFb (beta ¼ 0.16)c
0.13 (0.01) 0.02 (0.06, 0.10) 0.02 (0.06, 0.02) 0.01 (0.05, 0.07)
0.10 (0.01) 0.04 (0.05, 0.12) 0.03 (0.07, 0.01) 0.01 (0.06, 0.05)
1 SD increment 0.02 (0.02, 0.05) 0.01 (0.03, 0.01) 0.00 (0.02, 0.02)
Bedtime cortisol (tertile) 0.71 (0.29) REFb (beta ¼ 0.31)c REFb (beta ¼ 0.05)c REFb (beta ¼ 0.15)c
1.67 (0.32) 0.03 (0.05, 0.11) 0.01 (0.06, 0.03) 0.02 (0.07, 0.04)
5.04 (4.56) 0.04 (0.04, 0.12) 0.00 (0.04, 0.04) 0.00 (0.06, 0.06)
1 SD increment, log 0.01 (0.02, 0.05) 0.01 (0.02, 0.01) 0.01 (0.03, 0.02)
Mean cortisol (tertile) 4.66 (0.96) REFb (beta ¼ 0.27)c REFb (beta ¼ 0.04)c REFb (beta ¼ 0.14)c
6.85 (0.59) 0.06 (0.14, 0.02) 0.03 (0.07, 0.02) 0.03 (0.08, 0.03)
10.26 (2.34) 0.02 (0.06, 0.11) 0.04 (0.08, 0.00) 0.03 (0.09, 0.03)
1 SD increment 0.00 (0.03, 0.04) 0.02 (0.03, 0.00) 0.01 (0.03, 0.01)
N ¼ 3229.
Key: AH 4-I, Alice Heim 4-I; CAR, cortisol-awakening response; CI, conﬁdence interval; M, mean; REF, reference; SD, standard deviation.
a Cognitive data have been converted to z-scores for the analysis.
b Reference category; subscript beta shows the adjusted standardized cognitive decline in the reference category analysis adjusted for age, sex, education, ethnicity, waking
time, time between waking and ﬁrst measure of cortisol, seasonality, depressive symptoms, stress, Framingham cardiovascular risk score, coronary heart disease, stroke,
diabetes, CVD medication, and antidepressants.
c p < 0.01.
d p < 0.05.
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ﬁnding. None of the other associations differed from the null hy-
pothesis of no association (Table 2).
The association between cortisol in 2002/2004 and subsequent
cognitive decline are shown in Table 3. Over the mean 5.02 yearsTable 4
Change in cortisol between 2002/2004 and 2007/2009 and cognitive function in 2007/2
Change in cortisol measure M (SD) nmol/L Cognitive f
Memory
Beta (95% C
Waking cortisol (tertile) 11.51 (6.23) REF
0.97 (1.99) 0.05 (0.
9.15 (6.44) 0.02 (0.
1 SD increment, log 0.01 (0.
CAR (tertile) 16.62 (9.21) REF
1.44 (2.95) 0.04 (0.
14.15 (9.28) 0.03 (0.
1 SD increment 0.01 (0.
Diurnal slope (tertile) 0.01 (0.02) REF
0.01 (0.01) 0.03 (0.
0.04 (0.02) 0.00 (0.
1 SD increment 0.00 (0.
Bedtime cortisol (tertile) 2.72 (4.20) REF
0.32 (0.35) 0.01 (0.
3.24 (3.66) 0.00 (0.
1 SD increment, log 0.00 (0.
Mean cortisol (tertile) 3.75 (2.23) REF
0.28 (0.71) 0.04 (0.
3.38 (2.35) 0.02 (0.
1 SD increment 0.00 (0.
Analysis adjusted for age, sex, education, ethnicity, waking time, time between waking a
cardiovascular risk score, coronary heart disease, stroke, diabetes, CVD medication, and
N ¼ 2553.
Key: AH 4-I, Alice Heim 4-I; CAR, cortisol awakening response; CI, conﬁdence interval; M
a Cognitive data have been converted to z-scores for the analysis.follow-up there was decline in all cognitive tests, decline in the
reference group in the analysis (the lowest cortisol tertile) are
shown in Table 3, which also shows that higher cortisol values were
not associated with faster cognitive decline. The growth curve
approach (Supplementary Table S2) replicated the results obtained009a
unction
Reasoning (AH 4-I) Verbal ﬂuency
I) Beta (95% CI) Beta (95% CI)
REF REF
04, 0.14) 0.05 (0.03, 0.13) 0.04 (0.05, 0.12)
07, 0.11) 0.00 (0.08, 0.07) 0.03 (0.06, 0.11)
02, 0.04) 0.00 (0.03, 0.02) 0.02 (0.00, 0.05)
REF REF
05, 0.13) 0.05 (0.03, 0.13) 0.03 (0.11, 0.06)
12, 0.06) 0.06 (0.02, 0.13) 0.02 (0.11, 0.06)
04, 0.02) 0.02 (0.00, 0.05) 0.00 (0.03, 0.02)
REF REF
06, 0.12) 0.00 (0.08, 0.07) 0.01 (0.08, 0.09)
09, 0.09) 0.01 (0.07, 0.09) 0.02 (0.07, 0.11)
03, 0.04) 0.01 (0.02, 0.04) 0.01 (0.02, 0.04)
REF REF
08, 0.10) 0.03 (0.04, 0.11) 0.01 (0.08, 0.09)
09, 0.09) 0.04 (0.04, 0.12) 0.03 (0.06, 0.12)
03, 0.03) 0.02 (0.01, 0.04) 0.01 (0.02, 0.04)
REF REF
13, 0.05) 0.00 (0.07, 0.08) 0.08 (0.01, 0.17)
07, 0.10) 0.01 (0.06, 0.09) 0.01 (0.08, 0.09)
03, 0.03) 0.00 (0.02, 0.03) 0.00 (0.03, 0.03)
nd ﬁrst measure of cortisol, seasonality, depressive symptoms, stress, Framingham
antidepressants.
, mean; REF, reference; SD, standard deviation.
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stratiﬁed by sex (Supplementary Tables S3 and S4), there was some
evidence of greater decline in reasoning in women with high
bedtime cortisol, no such effects were seen in men.
Supplementary Table S5, presents results of the longitudinal
analysis on carries of the APOE e4 allele, these indicate that the
ﬂattest slope (b ¼ 0.13, 95% CI: 0.24, 0.02), and the highest
bedtime cortisol (b ¼ 0.12, 95% CI: 0.23, 0.01) were associated
with faster decline in verbal ﬂuency, no longitudinal associations
were observed in noncarrier of the APOE e4 (Supplementary
Table S6).
Between 2002/2004 and 2007/2009 waking cortisol declined
from a mean of 14.20 to 14.03 nmol/L (p < 0.001), CAR from 7.31 to
6.09 nmol/L (p< 0.001), mean cortisol from 7.26 to 7.05 nmol/L (p¼
0.003); the diurnal slope was ﬂatter at the second assessment
(0.131 to 0.116, p < 0.001) and bedtime cortisol higher
(1.58e1.90 nmol/L, p< 0.001). Results presented in Table 4 show no
associationbetweenchange incortisolmeasurebetween2002/2004
and 2007/2009 and cognitive tests in 2007/2009. Similarly, Table 5
shows that those with elevated levels of cortisol at both assess-
ments had cognitive score similar to those with low cortisol levels.4. Discussion
In this longitudinal analysis of the association between cortisol
and cognition in community dwelling participants we found no
evidence of a robust association between any feature of the diurnal
cortisol pattern or cortisol levels and cognitive decline or change in
cortisol levels and cognitive performance. The cross-sectional an-
alyses suggested better cognitive scores in those with higher
waking cortisol but these results were not consistent across the 2
data cycles, suggesting that this is a chance ﬁnding, perhaps
because of the large number of tests undertaken. No associations
were observed with memory, either in cross-sectional or longitu-
dinal analyses. Those with elevated cortisol levels at bothTable 5






First tertile in 2002/2004 and 2007/2009 331 REF
Others 1834 0.01 (
Third tertile in 2002/2004 and 2007/2009 388 0.01 (
CAR
First tertile in 2002/2004 and 2007/2009 313 REF
Others 1883 0.05 (
Third tertile in 2002/2004 and 2007/2009 357 0.12 (
Diurnal slope
First tertile in 2002/2004 and 2007/2009 379 REF
Others 1812 0.01 (
Third tertile in 2002/2004 and 2007/2009 362 0.05 (
Bedtime cortisol
First tertile in 2002/2004 and 2007/2009 369 REF
Others 1804 0.01 (
Third tertile in 2002/2004 and 2007/2009 380 0.10 (
Mean cortisol
First tertile in 2002/2004 and 2007/2009 359 REF
Others 1846 0.05 (
Third tertile in 2002/2004 and 2007/2009 348 0.02 (
Analysis adjusted for age, sex, education, ethnicity, waking time, time between waking
cardiovascular risk score, coronary heart disease, stroke, diabetes, CVD medication, and
N ¼ 2553.
Key: AH 4-I, Alice Heim 4-I; CAR, cortisol-awakening response; CI, conﬁdence interval; R
a Cognitive data have been converted to z-scores for the analysis.
b p < 0.05.assessments did not have poorer performance compared with
those with low levels, suggesting no evidence of chronic effects.
Most early studies examined the association of cortisol with
memory (Lupien et al., 1994, 1998; Seeman et al., 1997) with the
focus being on impact of change in cortisol on memory perfor-
mance. However, these studies were based on small samples,
ranging from 11 to 194 older adults; in such samples preclinical
dementia could have biased results, as the dementia disease pro-
cess is known to lead to dysregulation of the HPA axis and hyper-
cortisolemia (Csernansky et al., 2006; Weiner et al., 1997). More
recently, an increasingly number of studies has been based on
larger samples and assess multiple aspects of cognition. However,
these results are far from consistent. Serum cortisol appears not to
be associated with cognitive decline (Kalmijn et al., 1998; Schrijvers
et al., 2011) or dementia (Schrijvers et al., 2011). One study shows
low urinary cortisol, values in the lowest quartile, to be associated
with slower cognitive decline (Karlamangla et al., 2005).
Cortisol can be assessed using “average” measures, such as uri-
nary cortisol (Karlamangla et al., 2005; Seeman et al., 1997) or from
serum (Kalmijn et al., 1998; MacLullich et al., 2005; Schrijvers et al.,
2011). However, salivary cortisol is thought to be a better measure
of the biologically active hormone fraction (Kirschbaum and
Hellhammer, 1994; Vining et al., 1983), less inﬂuenced by physio-
logical and pharmacologic conditions than those based on urine or
serum (Kirschbaum and Hellhammer, 1989). Further advantages
include the study of the diurnal rhythm as an indicator of HPA axis,
healthy functioning being reﬂected in a strong diurnal pattern
(Adam and Kumari, 2009). Small (N < 200) studies on older adults
suggest that a ﬂatter slope is associated with poor verbal ﬂuency
(Fiocco et al., 2006) and greater decline in memory and executive
function (Beluche et al., 2010). Cross-sectional results from the
MIDUS study (N ¼ 1500) show healthier cortisol proﬁles (steeper
slope, higher waking, and lower bedtime cortisol) to be associated
with better executive function but not memory (Stawski et al.,
2011). In another study on 778 middle-aged men, higher overall
cortisol output was associated with poorer performance on a range/2009a
ve decline
y Reasoning (AH 4-I) Verbal ﬂuency
5% CI) Beta (95% CI) Beta (95% CI)
REF REF
0.10, 0.12) 0.01 (0.11, 0.09) 0.03 (0.08, 0.13)
0.13, 0.15) 0.02 (0.11, 0.14) 0.00 (0.14, 0.13)
REF REF
0.07, 0.16) 0.02 (0.08, 0.11) 0.13 (0.02, 0.23)b
0.02, 0.26) 0.01 (0.13, 0.11) 0.09 (0.04, 0.23)
REF REF
0.12, 0.09) 0.04 (0.13, 0.05) 0.04 (0.06, 0.14)
0.19, 0.08) 0.07 (0.19, 0.05) 0.05 (0.18, 0.08)
REF REF
0.12, 0.10) 0.00 (0.09, 0.09) 0.02 (0.12, 0.08)
0.23, 0.04) 0.04 (0.16, 0.08) 0.07 (0.20, 0.06)
REF REF
0.05, 0.16) 0.05 (0.04, 0.14) 0.01 (0.09, 0.11)
0.12, 0.16) 0.01 (0.12, 0.13) 0.04 (0.18, 0.09)
and ﬁrst measure of cortisol, seasonality, depressive symptoms, stress, Framingham
antidepressants.
EF, reference.
A. Singh-Manoux et al. / Neurobiology of Aging 35 (2014) 2239e22452244of cognitive tests, including memory; rather surprisingly, in this
study lower general cognitive ability at age 20 year was also asso-
ciated with higher midlife cortisol levels (Franz et al., 2011).
We found only one previous population based study (N ¼ 911)
that examined the association of diurnal salivary cortisol with
change in cognition and found an unhealthy diurnal proﬁle (lower
morning cortisol, higher evening cortisol, and ﬂatter slope) to be
associated with faster decline in memory in APOE-ε4 carriers but
not in noncarriers and no associations were apparent for executive
function and global cognitive score (Gerritsen et al., 2011). In the
Rotterdam Study on elderly individuals, APOE genotype did not
modify associations of serum cortisol with dementia (Schrijvers
et al., 2011). In our study, there was some evidence of a poor
diurnal proﬁle being associated with faster decline in verbal ﬂuency
(not memory or reasoning) in the APOE ε4 carriers.
The mechanisms underlying heterogeneity in cognitive aging
remain poorly understood; HPA axis dysfunction is one of the hy-
pothesized mechanisms with cortisol being a peripheral indicator.
However, cortisol-cognition association is not consistent, some
studies show no difference in the diurnal cortisol proﬁles of normal
and mildly impaired elderly participants (Wolf et al., 2002), others
show higher plasma cortisol to be associated with more rapid in-
crease in symptoms of dementia (Csernansky et al., 2006). It is
possible that cortisol-dementia association is subject to the effect of
preclinical dementia on HPA axis dysfunction; therefore, the cau-
sality issue remains unanswered (Hoschl and Hajek, 2001). Neu-
roimaging data are also not consistent, one study (N ¼ 99) suggests
that higher cortisol is associated with greater beta-amyloid depo-
sition, (Toledo et al., 2012) but another (N ¼ 95) found no associ-
ationwith brain volume (MacLullich et al., 2005). Our results, based
on a large sample of community-dwelling persons, suggest that
variability in HPA function is not associated with cognitive aging.
Our results must be considered in the context of study strengths
and limitations. Data come from a large study, response rate was
good, 6 measures over the day were used to study diurnal patterns,
the cognitive test battery was suitable for non-elderly populations
in that the tests were not affected by threshold effects. However,
cortisol was assessed on a single day and therefore subject to
imprecision in measurement and contextual effects despite inclu-
sion of a range of covariates in the analysis. A further source of error
is adherence to protocol in our study, which was self-reported via a
booklet. The cognitive test battery was chosen to examine the de-
terminants of heterogeneity in cognitive aging, not speciﬁcally the
effects of cortisol; it is possible that other domains of cognition are
associated with cortisol. Data collection procedure was cognitively
demanding and may have led to analysis on a selected sample. In
conclusion, our results show an effect of a ﬂatter slope and higher
bedtime cortisol on decline in verbal ﬂuency in those carrying the
APOE ε4 allele. However, given the lack of effects on memory and
the number of statistical tests undertaken we are moderately
conﬁdent that this represents a robust ﬁnding. There was no evi-
dence that HPA dysfunction is associated with cognitive perfor-
mance or decline in noncarriers of the APOE ε4 allele.
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